【招募受试者困难 辉瑞(PFE.US)终止淋巴瘤药物maplirpacept 2期临床试验】智通财经APP获悉,因招募受

智通财经
02 Jul
【招募受试者困难 辉瑞(PFE.US)终止淋巴瘤药物maplirpacept 2期临床试验】智通财经APP获悉,因招募受试者困难,辉瑞公司(PFE.US)已终止了靶向CD47的候选药物maplirpacept的二期临床试验。该药物是这家制药巨头于2021年8月以22.6亿美元收购Trillium Therapeutics时获得的核心资产。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10